EBV and Malignant Lymphoma with Special Emphasis on Pyothorax-Associated Lymphoma

Current Topics in Microbiology and Immunology - Epstein-Barr Virus and Human Cancer ◽

10.1007/978-3-642-56515-1_7 ◽

2001 ◽

pp. 103-120 ◽

Cited By ~ 2

Author(s):

K. Aozasa ◽

H. Kanno ◽

H. Miwa ◽

Y. Tomita

Keyword(s):

Malignant Lymphoma

Download Full-text

Adenocarcinoma of the breast metastatic to malignant lymphoma

JAMA ◽

10.1001/jama.195.11.963 ◽

1966 ◽

Vol 195 (11) ◽

pp. 963-965 ◽

Cited By ~ 1

Author(s):

G. L. Woolam

Keyword(s):

Malignant Lymphoma

Download Full-text

Clinicopathological study of primary malignant lymphoma of the large intestine in Japan

Gastroenterology ◽

10.1016/s0016-5085(01)81272-5 ◽

2001 ◽

Vol 120 (5) ◽

pp. A257-A257

Author(s):

K KAMIYA ◽

H GOTO ◽

Y NIWA ◽

N OHMIYA ◽

T HAYAKAWA

Keyword(s):

Malignant Lymphoma ◽

Large Intestine ◽

Clinicopathological Study

Download Full-text

Malignant lymphoma occurring in patient and pet

JAMA ◽

10.1001/jama.196.1.99 ◽

1966 ◽

Vol 196 (1) ◽

pp. 99-101 ◽

Cited By ~ 1

Author(s):

L. M. Drusin

Keyword(s):

Malignant Lymphoma

Download Full-text

Cases of Malignant Lymphoma which EUS-FNA was Useful for Diagnosis

Endoscopy ◽

10.1055/s-0031-1292204 ◽

2011 ◽

Vol 43 (S 03) ◽

Author(s):

Morishima Tomomasa

Keyword(s):

Malignant Lymphoma

Download Full-text

Primary Pituitary Malignant Lymphoma Was Difficult to Differentiate from Nonfunctioning Pituitary Adenoma: A Case Report

Journal of Neurological Surgery Part B Skull Base ◽

10.1055/s-0036-1592447 ◽

2016 ◽

Vol 77 (S 02) ◽

Author(s):

Yuta Murakami ◽

Shinya Jinguji ◽

Yugo Kishida ◽

Taku Sato ◽

Tadashi Watanabe ◽

...

Keyword(s):

Case Report ◽

Pituitary Adenoma ◽

Malignant Lymphoma ◽

Nonfunctioning Pituitary Adenoma

Download Full-text

11. International Conference on Malignant Lymphoma: Neue Therapieoptionen bei B- und T-Zell-Lymphomen

Onkologische Welt ◽

10.1055/s-0038-1631267 ◽

2011 ◽

Vol 02 (04) ◽

pp. 164-165

Author(s):

Alexander Kretzschmar

Keyword(s):

Malignant Lymphoma ◽

International Conference

Die auf dem 11. ICML-Kongress vorgestellten Studiendaten zeigen für Lenalidomid (Revlimid®)* eine wichtige Rolle bei der Entwicklung neuer Behandlungsoptionen jenseits der Chemotherapie beim diffus großzelligen B-Zell-Lymphom (DLBCL) als auch beim indolenten B-Zell NHL-Lymphom. Als neue Therapieoption bei peripheren T-Zell-Lymphomen (PTCL) werden auch die Histon-Deacetylase (HDAC)-Hemmer wie Romidepsin steigende Bedeutung erhalten, meinte Prof. Bertrand Coiffier, Lyon/Frankreich, von der renommierten GELA-Studiengruppe.

Download Full-text